Drug-Drug Interaction Study of ABP-671 in Gout Patients

Recruiting now · Phase 1

Conditions studied: Gout Chronic, Gout, DDI (Drug-Drug Interaction)

In brief

This is a open-Label, Within-Subject Drug-Drug Interaction Study of ABP-671 Added to Stable Allopurinol Therapy in Gout Patients. Pharmacokinetic (PK) interaction between ABP-671 and Allopurinol will be evaluated in participants who are on stable Allopurinol therapy.

Key facts

Study ID

NCT07367971

Run by

Atom Therapeutics Co., Ltd

People needed

20

Starts

2026-01-23

Expected to finish

2026-08-31

Last updated by the study team

2026-04-14

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults 18-75 years with clinical diagnosis of gout.
• Stable Allopurinol therapy QD for ≥14 days prior to Day 1.
• Cohort N: Normal renal function.
• Cohort R: Moderate renal impairment.

You may not qualify if…

• Clinically significant hepatic impairment.
• History of Allopurinol hypersensitivity.
• Pregnancy or breastfeeding.

Where it is running

• Wakefield Clinical Research — Cary, North Carolina, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.